HCMV-reactive T cells and uses therefor
AssigneeCity of Hope
InventorDon J. Diamond
Life of this patent
Estimating the term…
Abstract
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.
Claims16
A peptide selected from SEQ ID NOS:
- 10-25 and 30-41.
A vaccine against human cytomegalovirus comprising a peptide having a sequence selected from SEQ ID NOS:
- 1, 10-25 and 30-41 and a pharmaceutically acceptable carrier.
A cellular vaccine against human cytomegalovirus comprising antigen presenting cells that have been treated in vitro so as to present a peptide according to any one of SEQ ID NOS:
- 1, 10-25 and 30-41.
A recombinant viral vector vaccine which expresses a gene encoding a peptide according to any one of SEQ ID NOS:
- 1-14, 19, 26-28 and 30.
Dependencies are inferred from the claim text.